Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized phase II study of two induction treatments of melphalan, prednisolone, plus bortezomib, JCOG-MPB versus modified PETHEMA-MPB, in elderly patients or non-elderly patients refusing transplant with untreated symptomatic myeloma (JCOG1105, IMPROVE-MPB study)

Next Previous
X
Search
Trial Profile

Randomized phase II study of two induction treatments of melphalan, prednisolone, plus bortezomib, JCOG-MPB versus modified PETHEMA-MPB, in elderly patients or non-elderly patients refusing transplant with untreated symptomatic myeloma (JCOG1105, IMPROVE-MPB study)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 30 Aug 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bortezomib (Primary) ; Bortezomib (Primary) ; Melphalan (Primary) ; Prednisolone (Primary)
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Acronyms IMPROVE-MPB

    • Most Recent Events

    • 27 Aug 2022 Status changed from active, no longer recruiting to completed.
    • 01 Dec 2021 Results (n=82) assessing specific HLA alleles associated with Btz-related toxicities and treatment responses to Btz-containing therapy among Japanese patients with MM published in the Cancer Science
    • 21 Jun 2020 Results (n=79) exploratory analysis of single assessment criteria, presented at the 25th Congress of the European Haematology Association.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top